Statistics from Altmetric.com
randomised controlled trial (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes [RECORD]). ClinicalTrials.gov NCT00379769.
blinded (outcome adjudication committee).*
364 centres in 25 countries in Europe and Australasia.
4458 patients 40–75 years of age (mean age 58 y, 52% men) who had type 2 diabetes, body mass index >25 (mean 31) kg/m2, and haemoglobin (Hb) A1c concentration >7.0% to 9.0% (mean 7.9%) on maximum doses of metformin (MFN) or sulphonylurea (SFU). Exclusion criteria included hospital admission for a major cardiovascular (CV) event in ⩽3 months, planned CV intervention, and heart failure (HF).
rosiglitazone (RGZ), 4 mg/day, plus MFN or SFU, with starting doses determined by local practice (n = 2220); or MFN plus SFU (control) (n = 2227). Drug doses …
Source of funding GlaxoSmithKline.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.